Clinical trial NCT04287543 - References

Parkinson Disease — Melatonin on Clock Genes in Parkinson's Disease

Citation(s)

•   Abou-Sleiman PM, Muqit MM, Wood NW
  Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006 Mar;7(3):207-19. Review.
•   Anderson G, Seo M, Berk M, Carvalho AF, Maes M
  Gut Permeability and Microbiota in Parkinson's Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways. Curr Pharm Des. 2016;22(40):6142-6151. Review.
•   Barzilai A, Melamed E
  Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med. 2003 Mar;9(3):126-32. Review.
•   Belaid H, Adrien J, Karachi C, Hirsch EC, François C
  Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease. Sleep Med. 2015 Oct;16(10):1245-51. doi: 10.1016/j.sleep.2015.06.018. Epub 2015 Jul 14.
•   Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpening Z, Rogers N, Lewis SJ
  Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014 Mar;15(3):342-7. doi: 10.1016/j.sleep.2013.10.016. Epub 2014 Jan 21.
•   Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA
  Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014 May;71(5):589-595. doi: 10.1001/jamaneurol.2014.65.
•   Cai Y, Liu S, Sothern RB, Xu S, Chan P
  Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur J Neurol. 2010 Apr;17(4):550-4. doi: 10.1111/j.1468-1331.2009.02848.x. Epub 2009 Nov 12.
•   Cardinali DP, Pagano ES, Scacchi Bernasconi PA, Reynoso R, Scacchi P
  Melatonin and mitochondrial dysfunction in the central nervous system. Horm Behav. 2013 Feb;63(2):322-30. doi: 10.1016/j.yhbeh.2012.02.020. Epub 2012 Feb 25. Review.
•   Castellani RJ, Nunomura A, Rolston RK, Moreira PI, Takeda A, Perry G, Smith MA
  Sublethal RNA oxidation as a mechanism for neurodegenerative disease. Int J Mol Sci. 2008 May;9(5):789-806. doi: 10.3390/ijms9050789. Epub 2008 May 20.
•   Chung S, Bohnen NI, Albin RL, Frey KA, Müller ML, Chervin RD
  Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. J Clin Sleep Med. 2013 Nov 15;9(11):1131-7. doi: 10.5664/jcsm.3150.
•   Elbaz A, Carcaillon L, Kab S, Moisan F
  Epidemiology of Parkinson's disease. Rev Neurol (Paris). 2016 Jan;172(1):14-26. doi: 10.1016/j.neurol.2015.09.012. Epub 2015 Dec 21. Review.
•   Fernandez HH
  Updates in the medical management of Parkinson disease. Cleve Clin J Med. 2012 Jan;79(1):28-35. doi: 10.3949/ccjm.78gr.11005. Review.
•   Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K
  Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003 Dec;56(6):679-82.
•   Hoehn MM, Yahr MD
  Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42.
•   Innominato PF, Lim AS, Palesh O, Clemons M, Trudeau M, Eisen A, Wang C, Kiss A, Pritchard KI, Bjarnason GA
  The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2016 Mar;24(3):1097-105. doi: 10.1007/s00520-015-2883-6. Epub 2015 Aug 11.
•   Jankovic J
  An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006 Jul;73(4):682-9. Review.
•   Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX
  Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med. 2009 Jan-Feb;15(1-2):43-50. doi: 10.2119/molmed.2008.00117. Epub 2008 Nov 4. Review.
•   Lewy AJ, Sack RL, Miller LS, Hoban TM
  Antidepressant and circadian phase-shifting effects of light. Science. 1987 Jan 16;235(4786):352-4.
•   Mack JM, Schamne MG, Sampaio TB, Pértile RA, Fernandes PA, Markus RP, Prediger RD
  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms. Oxid Med Cell Longev. 2016;2016:3472032. Epub 2016 Oct 18. Review.
•   Mattam U, Jagota A
  Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration. Biogerontology. 2015 Feb;16(1):109-23. doi: 10.1007/s10522-014-9541-0. Epub 2014 Nov 28.
•   Mayo JC, Sainz RM, Tan DX, Antolín I, Rodríguez C, Reiter RJ
  Melatonin and Parkinson's disease. Endocrine. 2005 Jul;27(2):169-78. Review.
•   Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhães MC, de Lourdes Seabra M, de Bruin VM
  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007 Apr;254(4):459-64. Epub 2007 Apr 3.
•   Morisky DE, Ang A, Krousel-Wood M, Ward HJ
  Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008 May;10(5):348-54.
•   Ortiz GG, Benítez-King GA, Rosales-Corral SA, Pacheco-Moisés FP, Velázquez-Brizuela IE
  Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr Neuropharmacol. 2008 Sep;6(3):203-14. doi: 10.2174/157015908785777201.
•   Ortiz GG, Moráles-Sánchez EW, Pacheco-Moisés FP, Jiménez-Gil FJ, Macías-Islas MA, Mireles-Ramírez MA, González-Usigli H
  Effect of melatonin administration on cyclooxygenase-2 activity, serum levels of nitric oxide metabolites, lipoperoxides and glutathione peroxidase activity in patients with Parkinson’s disease. Gac Med Mex. 2017;153(Supl. 2):S72-S81. doi: 10.24875/GMM.M000008. Spanish.
•   Ortiz GG, Pacheco-Moisés FP, Gómez-Rodríguez VM, González-Renovato ED, Torres-Sánchez ED, Ramírez-Anguiano AC
  Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Metab Brain Dis. 2013 Dec;28(4):705-9. doi: 10.1007/s11011-013-9416-0. Epub 2013 May 24.
•   Panigel M
  [Application of new methods to the anatomical study of the human and animal placenta]. Bull Assoc Anat (Nancy). 1989 Sep;73(222):47-53. Review. French.
•   Perfeito R, Cunha-Oliveira T, Rego AC
  Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.
•   Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE
  Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Review.
•   Reiter RJ, Korkmaz A, Paredes SD, Manchester LC, Tan DX
  Melatonin reduces oxidative/nitrosative stress due to drugs, toxins, metals, and herbicides. Neuro Endocrinol Lett. 2008 Oct;29(5):609-13. Review.
•   Reiter RJ
  Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol. 1998 Oct;56(3):359-84. Review.
•   Shadrina MI, Slominsky PA, Limborska SA
  Molecular mechanisms of pathogenesis of Parkinson's disease. Int Rev Cell Mol Biol. 2010;281:229-66. doi: 10.1016/S1937-6448(10)81006-8. Review.
•   Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, Aarabi MH, Kouchaki E, Memarzadeh MR, Asemi Z
  The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Neurochem Int. 2017 Sep;108:183-189. doi: 10.1016/j.neuint.2017.03.014. Epub 2017 Mar 22.
•   Trotti LM, Bliwise DL
  Treatment of the sleep disorders associated with Parkinson's disease. Neurotherapeutics. 2014 Jan;11(1):68-77. doi: 10.1007/s13311-013-0236-z. Review.
•   Videnovic A, Golombek D
  Circadian Dysregulation in Parkinson's Disease. Neurobiol Sleep Circadian Rhythms. 2017 Jan;2:53-58. doi: 10.1016/j.nbscr.2016.11.001. Epub 2016 Nov 12.
•   Videnovic A, Willis GL
  Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease? Mov Disord. 2016 Mar;31(3):260-9. doi: 10.1002/mds.26509. Epub 2016 Jan 30. Review.
•   Videnovic A, Zee PC
  Consequences of Circadian Disruption on Neurologic Health. Sleep Med Clin. 2015 Dec;10(4):469-80. doi: 10.1016/j.jsmc.2015.08.004. Epub 2015 Sep 26. Review.
•   Vural EM, van Munster BC, de Rooij SE
  Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging. 2014 Jun;31(6):441-51. doi: 10.1007/s40266-014-0178-0. Review.
•   Weishaupt JH, Bartels C, Pölking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Hüther G, Schneider A, Bach A, Sirén AL, Hardeland R, Bähr M, Nave KA, Ehrenreich H
  Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res. 2006 Nov;41(4):313-23.
•   Zhang Y, Chen J, Qiu J, Li Y, Wang J, Jiao J
  Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: a dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr. 2016 Feb;103(2):330-40. doi: 10.3945/ajcn.115.124081. Epub 2015 Dec 30.

Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease

Details for clinical trial NCT04287543